AtriCure (NASDAQ:ATRC) Reaches New 12-Month Low – Here’s Why

AtriCure, Inc. (NASDAQ:ATRC) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $26.08 and last traded at $26.2950, with a volume of 510265 shares trading hands. The stock had previously closed at $27.80.

Analyst Upgrades and Downgrades

ATRC has been the topic of several analyst reports. JPMorgan Chase & Co. downgraded AtriCure from an “overweight” rating to a “neutral” rating and set a $36.00 price objective on the stock. in a report on Wednesday, February 11th. Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Citigroup restated an “outperform” rating on shares of AtriCure in a research report on Wednesday, February 18th. BTIG Research reiterated a “buy” rating and issued a $54.00 price objective on shares of AtriCure in a research report on Wednesday, February 18th. Finally, Canaccord Genuity Group increased their price objective on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $48.71.

AtriCure Price Performance

The company has a market cap of $1.33 billion, a PE ratio of -262.51 and a beta of 1.28. The firm’s 50-day moving average is $29.24 and its 200-day moving average is $34.28. The company has a quick ratio of 2.99, a current ratio of 3.96 and a debt-to-equity ratio of 0.13.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Tuesday, May 5th. The medical device company reported $0.00 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.07. AtriCure had a positive return on equity of 0.29% and a negative net margin of 0.83%.The business had revenue of $141.25 million for the quarter, compared to analysts’ expectations of $139.75 million. During the same period in the previous year, the firm posted ($0.14) EPS. The business’s revenue was up 14.3% on a year-over-year basis. AtriCure has set its FY 2026 guidance at 0.000-0.040 EPS. On average, equities analysts anticipate that AtriCure, Inc. will post 0.1 EPS for the current year.

Insider Buying and Selling at AtriCure

In related news, insider Vinayak Doraiswamy sold 5,000 shares of the company’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $29.83, for a total value of $149,150.00. Following the sale, the insider directly owned 96,875 shares of the company’s stock, valued at $2,889,781.25. This represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.00% of the stock is owned by corporate insiders.

Institutional Trading of AtriCure

A number of hedge funds have recently modified their holdings of ATRC. Aster Capital Management DIFC Ltd grew its position in shares of AtriCure by 197.1% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock worth $29,000 after buying an additional 538 shares during the period. Geneos Wealth Management Inc. bought a new position in shares of AtriCure in the 2nd quarter worth about $37,000. Farther Finance Advisors LLC lifted its position in AtriCure by 1,818.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,132 shares of the medical device company’s stock valued at $40,000 after acquiring an additional 1,073 shares during the period. First Horizon Corp purchased a new position in AtriCure during the 3rd quarter valued at about $42,000. Finally, Smartleaf Asset Management LLC boosted its stake in AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after acquiring an additional 429 shares in the last quarter. Institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.